Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Ibrutinib + Selinexor |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | chronic lymphocytic leukemia | predicted - sensitive | Ibrutinib + Selinexor | Case Reports/Case Series | Actionable | In a Phase I trial, Imbruvica (ibrutinib) and Xpovio (selinexor) combination therapy was tolerated and resulted in 1 complete response, 1 partial response, and 7 stable diseases among 9 patients with relapsed or refractory chronic lymphocytic leukemia harboring BTK C481S (PMID: 35608822; NCT02303392). | 35608822 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35608822) | Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. | Full reference... |